Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

GERN Relative to the S&P 500

GERN Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Geron Corp. (NASD:GERN) seasonal charts above shows that a Buy Date of May 8 and a Sell Date of September 9 has resulted in a geometric average return of 10.73% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 14 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 24.19% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company’s?drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various?rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

To download GERN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: GERN